Literature DB >> 11859469

Inhibitors of 5alpha -reductase type I in LNCaP cells from the roots of Angelica koreana.

Eun-Kyoung Seo, Kyeong Ho Kim, Min Ki Kim, Myung-Haing Cho, EunWook Choi, KiNam Kim, Woongchon Mar.   

Abstract

A prenylated coumarin, osthenol (1) and a sesquiterpene, bisabolangelone (2) have been isolated as active principles with 5alpha-reductase type I inhibitory effects in LNCaP cells from the roots of Angelica koreana Max. by bioassay-guided chromatographic fractionation. Osthenol exhibited a highly potent inhibitory activity on 5alpha-reductase type I in LNCaP cells with an IC50 value of 0.1 microg/ml, which is about 200 times more potent than the positive control, finasteride (IC50 = 19.8 microg/ml). Bisabolangelone also inhibited the activity of 5alpha-reductase type I in LNCaP cells (IC50 = 11.6 microg/ml), indicating that these compounds are possible candidates for the development of new drugs to treat human endocrine disorders associated with overproduction of DHT by 5 alpha-reductase type I. In addition, four compounds isooxypeucedanin, oxypeucedanin hydrate, oxypeucedanin and isoimperatorin were also isolated and found to be inactive in the 5alpha-reductase assay systems used in the present study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11859469     DOI: 10.1055/s-2002-20258

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  2 in total

Review 1.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

2.  Characterization of CYPs and UGTs Involved in Human Liver Microsomal Metabolism of Osthenol.

Authors:  Pil Joung Cho; Sanjita Paudel; Doohyun Lee; Yun Ji Jin; GeunHyung Jo; Tae Cheon Jeong; Sangkyu Lee; Taeho Lee
Journal:  Pharmaceutics       Date:  2018-08-30       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.